The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells

Clinical and Experimental Metastasis

Volumn 17, Issue 2, 1999, Pages 111-117

  Wylie, Stewart ^a   MacDonald, Ian C ^a   Varghese, Hemanth J ^a   Schmidt, Eric E ^a   Morris, Vincent L ^a   Groom, Alan C ^a   Chambers, Ann F ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Angiogenesis; Batimastat; Extravasation; Inhibitor; Matrix metalloproteinase; Metastasis

Indexed keywords

ANTIMETASTATIC AGENT; BATIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL SURVIVAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EXTRAVASATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER METASTASIS; MELANOMA B16; METASTASIS INHIBITION; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL MOVEMENT; CELL SURVIVAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; MELANOMA, EXPERIMENTAL; MESENTERIC VEINS; MICE; MICROSCOPY, VIDEO; NEOVASCULARIZATION, PATHOLOGIC; PHENYLALANINE; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0032782424     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006573417179     Document Type: Article

References (42)

1. DeClerk YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994; 30A: 2170-80.
2. Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 1995; 35: 293-301.
3. Rasmussen HA, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75: 69-75.
4. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
5. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51 (18 Suppl): 5054s-9s.
6. MacDougal JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14: 351-62.
7. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-70.
8. Denhardt DT. On the paradoxical ability of TIMPs either to inhibit or to promote the development and progression of the malignant phenotype. In: Hawkes SP, Edwards DR, Khokha R (eds) Inhibitors of Metalloproteinases in Development and Disease, Lausanne: Harwood Academic Publishers (1999) (in press).
9. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-74.
10. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996; 32A: 2528-33.
11. Parsons SL, Watson SA, Steele RJC. Phase I/II trials of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997; 23: 526-31.
12. Botos I, Scapozza L, Zhang D et al. Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci USA 1996; 93: 2749-54.
13. Davies B, Brown PD, East N et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-9.
14. Giavazzi R, Garofalo A, Ferri C et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 985-92.
15. Wang X, Fu X, Brown PD et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726-8.
16. Chirivi RG, Garofalo A, Crimmin MJ et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4.
17. Watson SA, Morris TM, Robinson G et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33.
18. Eccles SA, Box GM, Court WJ et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 1996; 56: 2815-22.
19. Nicolson GL. Molecular mechanisms of metastasis: tumor and host properties and the role of oncogenes and suppressor genes. Curr Opin Oncol 1991; 3: 75-92.
20. Fidler IJ. The biology of human cancer metastasis. Acta Oncol 1991; 30: 668-75.
21. Folkman J and Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
22. Chambers AF, MacDonald IC, Schmidt EE et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995; 14: 279-301.
23. Taraboletti G, Garofalo A, Belotti D et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8.
24. Fidler IJ. Selection of successive tumour lines for metastasis. Nature New Biol 1973; 242: 148-9.
25. Koop S, MacDonald IC, Luzzi K et al. Face of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res 1995; 55: 2520-3.
26. MacDonald I, Luzzi K, Grattan M et al. Preferential loss of micrometastases vs. individual cancer cells during experimental hematogenous metastasis. Proc Can Fed Biol Soc 1997; 40: 231 (abstract).
27. Luzzi KJ, MacDonald IC, Schmidt EE et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation, and limited survival of early micrometastases. Am J Path 1998; 153: 865-73.
28. Morris VL, Koop S, MacDonald IC et al. Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis 1994; 12: 357-67.
29. Morris VL, Schmidt EE, Koop S et al. Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis. Exp Cell Res 1995; 219: 571-8.
30. Koop S, Khokha R, Schmidt EE et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994; 54: 4791-7.
31. MacDonald IC, Schmidt EE, Morris VL et al. In vivo videomicroscopy of experimental hematogenous metastasis: cancer cell arrest, extravasation, and migration. In: Soll DR and Wessels D (eds) Motion Analysis of Living Cells 1998. New York: Wiley-Liss; 263-88.
32. MacPhee PJ, Schmidt EE, Groom AC. Intermittance of blood flow in liver sinusoids, studied by high-resolution in vivo microscopy. Am J Physiol 1995; 269 (Gastrointest Liver Physiol, 32): G692-8.
33. Rudolph AM, Heyman MA. The circulation of the fetus in utero: methods for studying distribution of blood flow, cardiac output and organ blood flow. Circ Res 1967; 21: 163-84.
34. Williams MA. Quantitative Methods in Biology. Chapter 2, Stereological Techniques. Amsterdam: North Holland Publishing Co 1977; pp. 5-84.
35. Khokha R, Zimmer MJ, Wilson SM et al. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 1992; 10: 365-70.
36. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299-304.
37. Koop S, Schmidt EE, MacDonald IC et al. Independence of metastatic ability and extravasation: metastatic ras-transformed and control fibroblasts extravasate equally well. Proc Natl Acad Sci USA 1996; 93: 11080-4.
38. Chosay JG, Fisher MA, Farhood A et al. Role of PECAM-1 (CD31) in neutrophil transmigration in murine models of liver and peritoneal inflammation. Am J Physiol 1998; 274 (Gastrointest Liver Physiol, 37): G776-82.
39. Booth CJ, Sundberg JP. Hemangiomas and hemangiosarcomas in inbred laboratory mice. Lab Animal Sci 1995; 45: 497-502.
40. Tanigaki Y, Saeki Y, Matsuhisa T et al. Antiangiogenic substance(s) in a tumor cell line with low metastatic potential originating from the BALB/c mouse liver. Invasion Metastasis 1995; 15: 70-80.
41. Lenzi R, Alpini G, Lui MH et al. Von Willebrand factor antigen is not an accurate marker of rat and guinea pig liver endothelial cells. Liver 1990; 10: 372-9.
42. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55: 1856-62.